MedStar Authors catalog › Details for: Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year Results.
Normal view MARC view ISBD view

Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year Results.

by Garcia-Garcia, Hector M; Waksman, Ron.
Citation: Journal of the American College of Cardiology. 2018 Sep 19.Journal: Journal of the American College of Cardiology.Published: ; 2018ISSN: 0735-1097.Full author list: Kandzari DE; Koolen JJ; Doros G; Massaro JJ; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R; BIOFLOW V Investigators.UI/PMID: 30257191.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: (Click here) Abbreviated citation: J Am Coll Cardiol. 2018 Sep 19.Local Holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007.Abstract: BACKGROUND: Coronary drug-eluting stent development has introduced new metal alloys, changes in stent architecture and bioresorbable polymers. Whether these advancements improve long-term clinical safety and efficacy has been inconsistent in prior studies.Abstract: OBJECTIVES: To compare late-term clinical outcomes among patients treated with an ultrathin strut (60 mum) bioresorbable polymer sirolimus-eluting stent (BP SES) and a thin strut (81 mum) durable polymer everolimus-eluting stent (DP EES) in a large randomized trial.Abstract: METHODS: BIOFLOW V was an international randomized trial comparing coronary revascularization with BP SES and DP EES regarding the primary endpoint of 12-month target lesion failure (TLF). Analysis of pre-specified 2-year clinical outcomes was performed.Abstract: RESULTS: Among 1,334 patients randomized to treatment with BP SES (884 patients) or DP EES (450 patients), the two-year TLF rate was 7.5% for BP SES and 11.9% for DP EES (-4.33% treatment difference, 95% CI -8.16% to -0.91%, P=0.015), driven by differences in target vessel myocardial infarction (MI; 5.3% versus 9.5%, P=0.01) and ischemia-driven target lesion revascularization (TLR; 2.6% versus 4.9%, P=0.04). Rates of cardiac death or MI were 7.0% versus 10.4% for BP SES and DP EES, respectively (P=0.047). Late/very late definite stent thrombosis was statistically lower for BP SES compared with DP EES (0.1% versus 1.0%, P=0.045).Abstract: CONCLUSIONS: In a large randomized trial, significant differences in both TLF and target vessel-related MI persisted through 2 years favoring treatment with BP SES over DP EES. Significantly lower cumulative TLR and late/very late stent thrombosis were also observed with BP SES.Abstract: Copyright (c) 2018. Published by Elsevier Inc.

Powered by Koha